Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: Efficacy, safety, and biomarker results from Japanese patients phase II studies

British Journal of Cancer

Volumn 101, Issue 10, 2009, Pages 1676-1682

  Toi, M ^a,b   Iwata, H ^c   Fujiwara, Y ^d   Ito, Y ^e   Nakamura, S ^f   Tokuda, Y ^g   Taguchi, T ^h   Rai, Y ⁱ   Aogi, K ^j   Arai, T ^k   Watanabe, J ^l   Wakamatsu, T ^m   Katsura, K ^m   Ellis, C E ⁿ   Gagnon, R C ⁿ   Allen, K E ⁿ   Sasaki, Y ^o   Takashima, S ^j  

^a KYOTO UNIVERSITY   (Japan)

^b TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

^e CANCER INSTITUTE HOSPITAL   (Japan)

^f ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^g TOKAI UNIVERSITY HOSPITAL   (Japan)

^h OSAKA UNIVERSITY HOSPITAL   (Japan)

ⁱ SAGARA HOSPITAL   (Japan)

^j NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^k TOCHIGI CANCER CENTER   (Japan)

^l SHIZUOKA CANCER CENTER   (Japan)

^m Development and Medical Affairs Division   (Japan)

ⁿ GLAXOSMITHKLINE   (United States)

^o SAITAMA MEDICAL UNIVERSITY   (Japan)

more..

Author keywords

Biomarker; HER2; Lapatinib; Metastatic breast cancer; Monotherapy; Trastuzumab

Indexed keywords

ANTHRACYCLINE; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRY SKIN; DYSPNEA; FATIGUE; FEMALE; FEVER; HEART LEFT VENTRICLE FAILURE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; METASTASIS; MONOTHERAPY; MULTICENTER STUDY; MUTATION; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RHINOPHARYNGITIS; SIDE EFFECT; STOMATITIS; TREATMENT RESPONSE; VOMITING; WEIGHT;

EID: 70449517339     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605343     Document Type: Article

References (28)

1. Arpino G, Wiechmann C, Osborne CK, Schiff R (2008) Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 29: 217-233
2. Bendell J, Domchek S, Burstein H, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97: 2972-2977
3. Blackwell K, Pegram M, Tan-Chiu E (2009) Single-Agent lapatinib for the treatment of HER2-overexpressing advanced or metastatic breast cancer that progressed on first-or second-line trastuzumab containing regimens. Ann Oncol 20: 1026-1031
4. Burstein HJ, Storniolo AM, Franco S, Forster J, Stein S, Rubin S, Salazar VM, Blackwell KL (2008) A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol 19: 1068-1074
5. Clayton AJ, Danson S, Jolly S, Ryder WD, Burt PA, Stewart AL, Wilkinson PM, Welch RS, Magee B, Wilson G, Howell A, Wardley AM (2004) Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 91: 639-643
6. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639-2648
7. Cui X, Schiff R, Arpino G, Osborne CK, Lee AV (2005) Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 23: 7721-7735
8. Di Leo A, Gomez HL, Aziz Z, Zvirbule Z, Bines J, Arbushites MC, Guerrera SF, Koehler M, Oliva C, Stein SH, Williams LS, Dering J, Finn RS, Press MF (2008) Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 26: 5444-5552
9. Gomez H, Doval D, Chavez M, Ang PC, Aziz Z, Nag S, Ng C, Franco SX, Chow LW, Arbushites MC, Casey MA, Berger MS, Stein SH, Sledge GW (2008) Efficacy and safety of lapatinib as first-line therapy for HER2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 26: 2999-3005
10. Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR, Michaud LB, Gonzalez-Angulo AM, Hortobagyi GN, Esteva FJ (2006) Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 24: 4107-4115
11. Geyer CE, Forster J, Lindquist D, Chan S, Romieu G, Peinkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355: 2733-2744
12. Johnston S, Trudeau M, Kaufman B, Boussen H, Blackwell K, LoRusso P, Lombardi DP, Ben Ahmed S, Citrin DL, DeSilvio ML, Harris J, Westlund RE, Salazar V, Zaks TZ, Spector NL (2008a) Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol 26: 1066-1072
13. Johnston S, Pegram M, Press M, Pippen J, Pivot X, Gomez H, Florance A, O'Rourke L, Maltzman J (2008b) Lapatinib combined with letrozole vs letrozole alone for front line postmenopausal hormone receptor positive (HR+) metastatic breast cancer (MBC): first results from the EGF30008 Trial. 31st Annual San Antonio Breast Cancer Symposium (SABCS): Abstract 46
14. Kang S, Bader A, Vogt P (2005) Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA 102: 802-807
15. Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, Harris GJ, Bullitt E, Van den Abbeele AD, Henson JW, Li X, Gelman R, Burstein HJ, Kasparian E, Kirsch DG, Crawford A, Hochberg F, Winer EP (2008) Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 26: 1993-1999
16. Marty M, Baselga J, Gatzemeier U (2003) Pooled analysis of six trials of trastuzumab (Herceptin): exploratory analysis of changes in left ventricular ejection fraction (LVEF) as a surrogate for clinical cardiac events (abstract). Breast Cancer Res Treat 82: S47
17. McCarty Jr KS, Szabo E, Flowers JL, Cox EB, Leight GS, Miller L, Konrath J, Soper JT, Budwit DA, Creasman WT, Seigler HF, McCarty Sr KS (1986) Use of a monoclonal anti-estrogen receptor antibody in the immuno-histochemical evaluation of human tumors. Cancer Res 46(suppl 8): 4244s-44248s
18. Montemurro F, Donadio M, Clavarezza M, Redana S, Jacomuzzi ME, Valabrega G, Danese S, Vietti-Ramus G, Durando A, Venturini M, Aglietta M (2006) Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. Oncologist 11: 318-324
19. Mukherjee A, Dhadda AS, Shehata M, Chan S (2007) Lapatinib: a tyrosine kinase inhibitor with a clinical role in breast cancer. Expert Opin Pharmacother 8: 2189-2204
20. Nahta R, Esteva F (2006) Molecular mechanisms of trastuzumab resistance. Breast Cancer Res 8: 215
21. Nahta R, Yuan LX, Du Y, Esteva FJ (2007) Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor 1 signaling. Mol Cancer Ther 6: 667-674
22. O'Shaughnessy J, Blackwell KL, Burstein H, Storniolo AM, Sledge G, Baselga J, Koehler M, Laabs S, Florance A, Roychowdhury D (2008) A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. J Clin Oncol 26 abstr 1015
23. Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS (2008) Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 83: 679-686
24. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182
25. Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, Perren T, Passalacqua R, Bighin C, Klijn JG, Ageev FT, Hitre E, Groetz J, Iwata H, Knap M, Gnant M, Muehlbauer S, Spence A, Gelber RD, Piccart-Gebhart MJ (2007) Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 25: 3859-3865
26. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726
27. Xia W, Husain I, Liu L, Bacus S, Saini S, Spohn J, Pry K, Westlund R, Stein SH, Spector NL (2007) Lapatinib antitumour activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in HER2-overexpressing breast cancers. Cancer Res 67: 1170-1175
28. Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, Owens G, Alligood KJ, Spector NL (2002) Anti-tumour activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/HER2 and downstream Erk1/2 and AKT pathways. Oncogene 21: 6255-6263